Markey researcher to investigate key drivers of lung cancer metastasis
LEXINGTON, Ky. (July 12, 2024) — University of Kentucky Markey Cancer Center researcher Guan-Yu Xiao, Ph.D., has received a three-year $747,000 grant from the National Cancer Institute (NCI) to study how lung cancer metastasizes, or spreads to other parts of the body.
Xiao’s research focuses on lung adenocarcinoma, a subtype of non-small cell lung cancer and the most common form of lung cancer. Treatment options for metastatic lung adenocarcinoma are limited – many patients do not respond well to available treatments or develop resistance to them over time.
By giving scientists a better understanding of the cellular processes driving lung cancer metastasis, Xiao’s study could potentially lead to new treatments and may also address the challenge of resistance to current therapies.
“Findings from this study could open new avenues for treatment that would offer hope for patients whose current therapies have stopped working,” said Xiao, an assistant professor in the UK College of Medicine’s department of Toxicology and Cancer Biology. “The potential impact also extends beyond lung cancer, possibly offering insights for treating a range of cancer types.”
The new study will build upon Xiao’s previous findings, which show that a process called epithelial-to-mesenchymal transition (EMT) helps drive metastasis by causing cancer cells to release substances that help them invade nearby tissues and avoid the body’s immune defenses.
Xiao’s prior research also shows that blocking this release process could be a promising new treatment strategy. His team identified a protein called Rab6A that regulates the process and would play a key role in therapeutic development.
The NCI grant will allow Xiao to study how Rab6A affects cancer growth and spread by regulating the EMT secretion process. Findings from the mouse study could help scientists develop drugs that target Rab6A or related proteins, potentially leading to new strategies for preventing metastasis in patients with cancer.
Xiao’s grant is part of the NCI’s Pathway to Independence Award program, which helps promising young scientists establish their research careers.
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R00CA249048. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
As the state’s flagship, land-grant institution, the University of Kentucky exists to advance the Commonwealth. We do that by preparing the next generation of leaders — placing students at the heart of everything we do — and transforming the lives of Kentuckians through education, research and creative work, service and health care. We pride ourselves on being a catalyst for breakthroughs and a force for healing, a place where ingenuity unfolds. It's all made possible by our people — visionaries, disruptors and pioneers — who make up 200 academic programs, a $476.5 million research and development enterprise and a world-class medical center, all on one campus.
In 2022, UK was ranked by Forbes as one of the “Best Employers for New Grads” and named a “Diversity Champion” by INSIGHT into Diversity, a testament to our commitment to advance Kentucky and create a community of belonging for everyone. While our mission looks different in many ways than it did in 1865, the vision of service to our Commonwealth and the world remains the same. We are the University for Kentucky.